Moxifloxacin vs. Polytrim for Conjunctivitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00581542 |
Recruitment Status
:
Completed
First Posted
: December 27, 2007
Results First Posted
: January 18, 2016
Last Update Posted
: January 18, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Conjunctivitis | Drug: moxifloxacin Drug: polytrim | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 124 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis. |
Study Start Date : | March 2007 |
Actual Primary Completion Date : | March 2009 |
Actual Study Completion Date : | March 2012 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Moxifloxacin Opthalmic solution |
Drug: polytrim
1-2 drops four times a day for 8-10 days.
|
Active Comparator: Polymyxin B-trimethoprim opthalmic solution |
Drug: moxifloxacin
1-2 drops three times a day for 8-10 days.
|
- Number of Participants With Normal Physical Examination of the Eye [ Time Frame: 10 days ]
- Number of Participants With a Negative Bacterial Culture [ Time Frame: 10 days ]Conjunctival swab specimens were inoculated onto tryptic soy agar with 5% sheep blood and GC II agar supplemented with hemoglobin and isovialex with incubation at 35 degrees C in ambient air supplemented with 5% carbon dioxide for 48 hours. S pneumoniae, H influenzai and M Catarrhalis were identified.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Year to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 1 - 18 years of age with presumed bacterial conjunctivitis.
Exclusion Criteria:
- Previous antibiotics or to receive systemic antibiotic.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00581542
United States, New York | |
University of Rochester | |
Rochester, New York, United States, 14642 |
Principal Investigator: | Francis Gigliotti, MD | University of Rochester |
Responsible Party: | Frank Gigliotti, Professor, University of Rochester |
ClinicalTrials.gov Identifier: | NCT00581542 History of Changes |
Other Study ID Numbers: |
RSRB #17454 |
First Posted: | December 27, 2007 Key Record Dates |
Results First Posted: | January 18, 2016 |
Last Update Posted: | January 18, 2016 |
Last Verified: | December 2015 |
Additional relevant MeSH terms:
Conjunctivitis Conjunctival Diseases Eye Diseases Pharmaceutical Solutions Ophthalmic Solutions Moxifloxacin Fluoroquinolones Norgestimate, ethinyl estradiol drug combination Anti-Bacterial Agents Anti-Infective Agents Topoisomerase II Inhibitors |
Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Contraceptives, Oral, Combined Contraceptives, Oral Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents Physiological Effects of Drugs Nucleic Acid Synthesis Inhibitors |